Advertisement

Citations to this article

Federica Di Nicolantonio, Sabrina Arena, Josep Tabernero, Stefano Grosso, Francesca Molinari, Teresa Macarulla, Mariangela Russo, Carlotta Cancelliere, Davide Zecchin, Luca Mazzucchelli, Takehiko Sasazuki, Senji Shirasawa, Massimo Geuna, Milo Frattini, José Baselga, Margherita Gallicchio, Stefano Biffo, Alberto Bardelli
Published in Volume 120, Issue 8
J Clin Invest. 2010; 120(8):2858–2866 doi:10.1172/JCI37539

Total citations by year in Crossref

Year: 2014 2013 2012 2011 Total
Citations: 15 21 14 13 63
Citation information

Citations to this article in Crossref (63)

Title and authors Publication Year
Dual Inhibition of Phosphatidylinositol 3′-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach for Mucinous Adenocarcinoma of the Ovary:
A Kudoh, T Oishi, H Itamochi, S Sato, J Naniwa, S Sato, M Shimada, J Kigawa, T Harada
International Journal of Gynecological Cancer 2014
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
J Rodon, I Braña, LL Siu, MJ Jonge, N Homji, D Mills, E Tomaso, C Sarr, L Trandafir, C Massacesi, F Eskens, JC Bendell
Investigational New Drugs 2014
Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment
H Cheng, M Shcherba, G Pendurti, Y Liang, B Piperdi, R Perez-Soler
Lung Cancer Management 2014
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
J Polivka, F Janku
Pharmacology & Therapeutics 2014
PIK3CA Mutations in Mucinous Cystic Neoplasms of the Pancreas:
D Garcia-Carracedo, ZM Chen, W Qiu, AS Huang, SM Tang, RH Hruban, GH Su
Pancreas 2014
The Search Continues: Looking for Predictive Biomarkers for Response to Mammalian Target of Rapamycin Inhibition in Endometrial Cancer
LA Meyer, BM Slomovitz, B Djordjevic, SN Westin, DA Iglesias, MF Munsell, Y Jiang, R Schmandt, RR Broaddus, RL Coleman, JM Galbincea, KH Lu
International Journal of Gynecological Cancer 2014
PI3K/AKT signaling pathway and cancer: an updated review
M Martini, MC de Santis, L Braccini, F Gulluni, E Hirsch
Annals of Medicine 2014
Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
F Janku, DS Hong, S Fu, SA Piha-Paul, A Naing, GS Falchook, AM Tsimberidou, VM Stepanek, SL Moulder, JJ Lee, R Luthra, RG Zinner, RR Broaddus, JJ Wheler, R Kurzrock
Cell Reports 2014
Analysis of Molecular Cytogenetic Changes in Metastatic Renal Cell Carcinoma in the Setting of Everolimus Treatment: A Pilot Project
IR Caldwell, P Oei, D Ng, B Caudwell, PC Fong, RJ Broom
Clinical Genitourinary Cancer 2014
Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends
MS Matter, T Decaens, JB Andersen, SS Thorgeirsson
Journal of Hepatology 2014
mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: A critical review
N Husseinzadeh, HD Husseinzadeh
Gynecologic Oncology 2014
A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: A Gynecologic Oncology Group study
SM Campos, WE Brady, KM Moxley, RE O'Cearbhaill, PS Lee, PA DiSilvestro, J Rotmensch, PG Rose, PH Thaker, DM O'Malley, P Hanjani, RE Zuna, ML Hensley
Gynecologic Oncology 2014
Precision medicine for metastatic renal cell carcinoma
G Sonpavde, TK Choueiri
Urologic Oncology: Seminars and Original Investigations 2014
Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents
HK Kim, JE Green
Pharmacogenomics 2014
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study
M Wang, LL Popplewell, RH Collins, JN Winter, A Goy, MS Kaminski, NL Bartlett, PB Johnston, J Lister, SR Fanning, JM Tuscano, JT Beck, H Kaya, A Robeva, J Fan, J Klimovsky, W Cheung, A Cherfi, OA O'Connor
British Journal of Haematology 2014
New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer:
C Vicier, MV Dieci, F Andre
Current Opinion in Oncology 2013
Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients
B Karakas, D Colak, N Kaya, H Ghebeh, A Al-Qasem, F Hendrayani, M Toulimat, T Al-Tweigeri, BH Park, A Aboussekhra
Cancer biology & therapy 2013
New Hypothesis on Pathogenesis of Ovarian Cancer Lead to Future Tailored Approaches
P Rescigno, I Cerillo, R Ruocco, C Condello, SD Placido, M Pensabene
BioMed Research International 2013
Current Phase II clinical data for ridaforolimus in cancer
A Spreafico, HJ Mackay
Expert Opinion on Investigational Drugs 2013
Translation factors and ribosomal proteins control tumor onset and progression: how?
F Loreni, M Mancino, S Biffo
Oncogene 2013
Ribosomal proteins as novel players in tumorigenesis
A las Heras-Rubio, L Perucho, R Paciucci, J Vilardell, ME LLeonart
Cancer and Metastasis Reviews 2013
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
KS Saini, S Loi, E Azambuja, O Metzger-Filho, ML Saini, M Ignatiadis, JE Dancey, MJ Piccart-Gebhart
Cancer Treatment Reviews 2013
Targeting PI3K, HER2 and the IL-8/JAK2 axis in metastatic breast cancer: Which combination makes the whole greater than the sum of its parts?
A Britschgi, T Radimerski, M Bentires-Alj
Drug Resistance Updates 2013
Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: Outcome and results of KRAS mutational analysis in plasma
KL Spindler, MM Sorensen, N Pallisgaard, RF Andersen, BM Havelund, J Ploen, U Lassen, AK Jakobsen
Acta Oncologica 2013
Everolimus in colorectal cancer
I Altomare, H Hurwitz
Expert Opinion on Pharmacotherapy 2013

Advertisement
Advertisement